Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Scopolamine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor
Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Scopolamine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : IND Enabling
Sponsor : US Department of Defense
Deal Size : Undisclosed
Deal Type : Funding
Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : IND Enabling
Sponsor : US Department of Defense
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Scopolamine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Motion Sickness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2020
Lead Product(s) : Scopolamine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable